Press releases
Sorted by date
- November 7, 2024 - Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
- November 7, 2024 - Transgene Reports Business, Pipeline and Financial Update for Q3 2024
- November 5, 2024 - Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
- October 14, 2024 - Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- September 24, 2024 - Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
- September 14, 2024 - Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
- September 10, 2024 - Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
- September 9, 2024 - Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
- September 5, 2024 - Transgene to Participate in HTID Conference and Investor Access Forum in Paris
- August 27, 2024 - Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
- July 30, 2024 - Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH
- July 22, 2024 - Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
- June 3, 2024 - Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- May 15, 2024 - Transgene’s Combined General Meeting of May 15, 2024
- May 14, 2024 - Transgene provides business and financial update for Q1 2024
- April 24, 2024 - Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024
- April 11, 2024 - Availability of Transgene’s 2023 Universal Registration Document
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 27, 2024 - Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
- March 27, 2024 - Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- March 18, 2024 - Transgene Announces Upcoming Investor Meetings
- March 6, 2024 - Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
- March 5, 2024 - Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
- January 22, 2024 - Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
- January 22, 2024 - Transgene Announces Financial Calendar for 2024
- January 8, 2024 - Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
- December 21, 2023 - Transgene Announces Upcoming Investor Meetings
- December 5, 2023 - Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
- November 7, 2023 - Transgene reports business update and Q3 2023 financial position
- October 10, 2023 - Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
- September 20, 2023 - Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
- September 14, 2023 - Transgene Announces Upcoming Investor Meetings
- July 17, 2023 - Transgene receives $15.3 Million from the Sale of Securities Held for Sale
- June 6, 2023 - Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- June 5, 2023 - Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25, 2023 - Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
- May 10, 2023 - Transgene provides business update and Q1 2023 financial position
- May 10, 2023 - Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
- May 5, 2023 - Transgene’s Combined General Meeting of May 5, 2023
- May 5, 2023 - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- April 18, 2023 - New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
- April 17, 2023 - Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
- April 12, 2023 - Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
- April 11, 2023 - Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
- April 6, 2023 - Availability of Transgene’s 2022 Universal Registration Document
- April 4, 2023 - Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
- March 27, 2023 - Transgene Announces Upcoming Investor Meetings
- March 16, 2023 - Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
- March 15, 2023 - Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- March 9, 2023 - Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
- January 6, 2023 - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
- January 4, 2023 - Transgene announces Financial Calendar for 2023
- December 15, 2022 - Transgene Announces Upcoming Investor Meetings
- November 14, 2022 - Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
- November 7, 2022 - Transgene reports business update and Q3 2022 financial position
- November 2, 2022 - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- September 12, 2022 - Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
- September 7, 2022 - Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
- August 31, 2022 - Transgene announces Upcoming Investor Meetings
- June 28, 2022 - Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
- June 27, 2022 - Transgene and BioInvent announce positive progress for BT-001
- June 6, 2022 - Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- May 27, 2022 - Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
- May 25, 2022 - Transgene’s Combined General Meeting of May 25, 2022
- May 17, 2022 - Transgene Announces Upcoming Investor Meetings
- May 10, 2022 - All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
- April 8, 2022 - Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
- April 7, 2022 - Availability of Transgene’s 2021 Universal Registration Document
- April 5, 2022 - Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
- March 31, 2022 - Transgene’s Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman
- March 16, 2022 - Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
- March 9, 2022 - Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
- March 9, 2022 - Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
- February 10, 2022 - Transgene appoints Steven Bloom as Chief Business Officer
- January 20, 2022 - Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
- January 18, 2022 - Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
- January 6, 2022 - Transgene announces Financial Calendar for 2022
- December 15, 2021 - Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
- November 22, 2021 - Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
- November 4, 2021 - Transgene reports business update and Q3 2021 financial position
- October 1, 2021 - Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
- September 22, 2021 - Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
- September 16, 2021 - Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
- September 13, 2021 - Transgene Announces Upcoming Investor Meetings
- September 1, 2021 - Transgene Participates in New Cancer Research Consortium
- June 28, 2021 - First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- June 24, 2021 - First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
- June 22, 2021 - Transgene announces the success of its Capital Increase via a Private Placement
- June 21, 2021 - Transgene Launches a Capital Increase via a Private Placement
- June 8, 2021 - Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
- May 27, 2021 - Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
- May 26, 2021 - Combined General Meeting of May 26, 2021
- April 27, 2021 - Transgene reports business update and end Q1 2021 financial position
- April 12, 2021 - Transgene Announces Upcoming Investor Meetings
- April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
- April 7, 2021 - Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
- April 1, 2021 - Availability of Transgene’s 2020 Universal Registration Document
- March 10, 2021 - Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
- March 10, 2021 - Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
- March 2, 2021 - Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
- March 1, 2021 - Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
- January 21, 2021 - First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- January 19, 2021 - Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
- January 14, 2021 - Transgene Appoints Gaëlle Stadtler as Director of Human Resources
- December 21, 2020 - Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
- December 17, 2020 - Transgene Announces Financial Calendar for 2021
- December 16, 2020 - Transgene Announces Investor Meetings for January 2021
- December 3, 2020 - Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
- December 3, 2020 - Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
- November 9, 2020 - Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- November 9, 2020 - Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
- November 5, 2020 - Transgene reports business update and end Q3 2020 financial position
- November 5, 2020 - Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
- October 27, 2020 - Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- October 19, 2020 - Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- October 15, 2020 - Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- October 6, 2020 - Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
- September 16, 2020 - Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022
- September 9, 2020 - Transgene Announces Upcoming Investor Meetings
- September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
- August 4, 2020 - Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
- July 22, 2020 - Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
- July 9, 2020 - Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
- June 22, 2020 - Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
- June 22, 2020 - Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
- May 27, 2020 - Combined General Meeting of May 27, 2020
- May 15, 2020 - Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
- May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
- May 6, 2020 - Transgene reports Q1 2020 financial position and business update
- May 4, 2020 - Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses
- April 3, 2020 - Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19
- April 3, 2020 - Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
- March 11, 2020 - Major R&D milestones achieved in 2019 and strong clinical activity in 2020
- March 3, 2020 - Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
- February 20, 2020 - First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
- January 7, 2020 - Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
- December 18, 2019 - Transgene Announces Financial Calendar for 2020
- December 12, 2019 - Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
- December 11, 2019 - Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
- December 9, 2019 - Transgene Announces Investor Meetings for January 2020
- November 14, 2019 - Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
- October 22, 2019 - Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
- September 30, 2019 - Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
- September 18, 2019 - Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
- September 16, 2019 - Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
- August 29, 2019 - Transgene Announces Upcoming Investor Meetings
- August 7, 2019 - Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
- August 2, 2019 - Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
- July 18, 2019 - Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
- July 10, 2019 - Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
- July 2, 2019 - Success of Transgene’s €48.7 Million Rights Issue
- June 14, 2019 - Transgene Announces the Launch of a Rights Issue
- June 5, 2019 - Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
- May 27, 2019 - Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
- May 22, 2019 - Combined General Meeting of May 22, 2019
- May 13, 2019 - Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019
- May 13, 2019 - Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
- May 9, 2019 - Transgene Announces Upcoming Investor Meetings
- May 9, 2019 - Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
- May 2, 2019 - Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
- March 26, 2019 - Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
- March 20, 2019 - Transgene: A positive 2018, moving ahead with a strong portfolio
- March 18, 2019 - Transgene secures a €20 Million Revolving Credit Facility with Natixis
- March 13, 2019 - NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
- March 5, 2019 - Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
- December 20, 2018 - Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
- December 17, 2018 - Transgene Announces Financial Calendar for 2019
- December 5, 2018 - Transgene Announces Upcoming Investor Meetings
- November 12, 2018 - Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
- November 7, 2018 - Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
- November 7, 2018 - Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
- October 30, 2018 - NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
- October 25, 2018 - €26.6 million in cash and cash equivalents as of September 30, 2018
- October 17, 2018 - First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
- October 10, 2018 - Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
- October 2, 2018 - Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
- September 24, 2018 - Transgene unveils myvac™, an individualized immunotherapy against solid tumors
- September 19, 2018 - Transgene Presents 2018 Half-Year Results and Business Update
- September 3, 2018 - Transgene Announces Upcoming Investor Meetings
- August 20, 2018 - Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
- July 10, 2018 - Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
- June 4, 2018 - Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
- May 24, 2018 - Transgene Announces Upcoming Investor Meetings
- May 23, 2018 - Combined General Meeting of May 23, 2018
- May 17, 2018 - Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
- May 2, 2018 - Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
- April 26, 2018 - €35.6 Million in Cash and Cash Equivalents as of March 31, 2018
- April 18, 2018 - Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
- March 21, 2018 - Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
- March 15, 2018 - Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
- January 17, 2018 - First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
- January 16, 2018 - First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
- December 21, 2017 - Transgene Announces Financial Calendar for 2018
- December 18, 2017 - Transgene Announces Upcoming Investor Meetings
- December 6, 2017 - BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
- November 10, 2017 - Transgene successfully raises € 14.4 million from U.S. and European investors
- October 30, 2017 - Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
- October 26, 2017 - First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
- October 23, 2017 - TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
- October 19, 2017 - Third Quarter Marked by Progress in Clinical Development and Research
- October 17, 2017 - Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
- October 12, 2017 - Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
- October 2, 2017 - Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
- September 21, 2017 - Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
- September 19, 2017 - First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
- September 13, 2017 - First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
- September 11, 2017 - Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
- September 7, 2017 - Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
- August 31, 2017 - Transgene Announces Upcoming Investor Meetings
- July 31, 2017 - First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
- July 24, 2017 - Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
- June 29, 2017 - Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
- June 22, 2017 - Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
- June 8, 2017 - Combined General Meeting of June 8, 2017
- April 25, 2017 - €50.7 Million in Cash and Cash Equivalents as of March 31, 2017
- April 25, 2017 - Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
- April 24, 2017 - SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
- April 19, 2017 - Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
- April 12, 2017 - Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
- April 10, 2017 - Transgene Announces Upcoming Investor Meetings and R&D Day
- March 30, 2017 - Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
- March 20, 2017 - Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
- March 13, 2017 - First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
- February 13, 2017 - Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
- January 5, 2017 - Transgene Announces Financial Calendar for 2017
- December 22, 2016 - Transgene Announces Upcoming Investor Events
- December 7, 2016 - UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb
- November 14, 2016 - Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting
- November 10, 2016 - Successful Completion of Transgene’s Rights Issue – Gross proceeds of circa €46.4 million
- October 28, 2016 - Transgene Announces Publication in OncoImmunology of Pre-Clinical Data Demonstrating Delivery of a Fully Functional Immune Checkpoint Inhibitor (ICI) with Anti-Tumor Efficacy by a New Generation of Oncolytic Viral Immunotherapy
- October 20, 2016 - Transgene Reports Third Quarter 2016 Financial Results
- October 20, 2016 - Transgene Announces Rights Issue
- October 17, 2016 - First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
- October 11, 2016 - Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
- October 5, 2016 - Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines
- September 5, 2016 - Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
- September 1, 2016 - Transgene Announces Participation at Upcoming Investor Events
- July 21, 2016 - Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
- May 31, 2016 - Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
- May 25, 2016 - Composition of the Board of Directors and Statutory Auditors
- April 21, 2016 - Transgene Reports First Quarter 2016 Business Update
- April 19, 2016 - Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)
- March 17, 2016 - Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team
- March 8, 2016 - Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)
- March 2, 2016 - Transgene Announces Participation at Upcoming Investor Events
- February 3, 2016 - Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset
- January 28, 2016 - EIB lends EUR 20m to Transgene
- January 8, 2016 - Transgene Announces Financial Calendar for 2016
- January 7, 2016 - Transgene enters new phase in its strategic development
- January 6, 2016 - Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
- December 23, 2015 - Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
- November 12, 2015 - Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
- November 4, 2015 - Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
- October 21, 2015 - Transgene Reports Third Quarter 2015 Financial Results
- September 23, 2015 - Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
- September 10, 2015 - Transgene Reports Financial Results for First Six Months of 2015 (interim report)
- September 8, 2015 - Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
- August 19, 2015 - Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
- June 29, 2015 - Transgene plans restructuring to focus on research and development
- June 1, 2015 - Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
- May 18, 2015 - Transgene Announces Participation at Upcoming Investor Events
- April 23, 2015 - Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
- April 22, 2015 - Transgene Reports First Quarter 2015 Financial Results
- April 21, 2015 - Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
- April 16, 2015 - Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
- March 24, 2015 - Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)
- March 19, 2015 - Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR
- January 8, 2015 - Transgene Announces Financial Calendar for 2015
- October 21, 2014 - Transgene Announces Third Quarter 2014 Financial Results
- September 8, 2014 - Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010
- April 22, 2014 - Transgene Reports First Quarter 2014 Financial Results
- March 26, 2014 - Transgene Reports Fiscal Year 2013 Results and Provides Business Update
- November 7, 2024 - Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
- November 7, 2024 - Transgene Reports Business, Pipeline and Financial Update for Q3 2024
- November 5, 2024 - Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
- October 14, 2024 - Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- September 24, 2024 - Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
- September 14, 2024 - Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
- September 10, 2024 - Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
- September 9, 2024 - Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
- September 5, 2024 - Transgene to Participate in HTID Conference and Investor Access Forum in Paris
- August 27, 2024 - Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
- July 30, 2024 - Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH
- July 22, 2024 - Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
- June 3, 2024 - Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- May 15, 2024 - Transgene’s Combined General Meeting of May 15, 2024
- May 14, 2024 - Transgene provides business and financial update for Q1 2024
- April 24, 2024 - Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024
- April 11, 2024 - Availability of Transgene’s 2023 Universal Registration Document
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 27, 2024 - Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- March 27, 2024 - Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
- March 18, 2024 - Transgene Announces Upcoming Investor Meetings
- March 6, 2024 - Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
- March 5, 2024 - Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
- January 22, 2024 - Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
- January 22, 2024 - Transgene Announces Financial Calendar for 2024
- January 8, 2024 - Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
- December 21, 2023 - Transgene Announces Upcoming Investor Meetings
- December 5, 2023 - Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
- November 7, 2023 - Transgene reports business update and Q3 2023 financial position
- October 10, 2023 - Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
- September 20, 2023 - Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
- September 14, 2023 - Transgene Announces Upcoming Investor Meetings
- July 17, 2023 - Transgene receives $15.3 Million from the Sale of Securities Held for Sale
- June 6, 2023 - Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- June 5, 2023 - Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25, 2023 - Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
- May 10, 2023 - Transgene provides business update and Q1 2023 financial position
- May 10, 2023 - Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
- May 5, 2023 - Transgene’s Combined General Meeting of May 5, 2023
- May 5, 2023 - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- April 18, 2023 - New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
- April 17, 2023 - Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
- April 12, 2023 - Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
- April 11, 2023 - Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
- April 6, 2023 - Availability of Transgene’s 2022 Universal Registration Document
- April 4, 2023 - Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
- March 27, 2023 - Transgene Announces Upcoming Investor Meetings
- March 16, 2023 - Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
- March 15, 2023 - Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- March 9, 2023 - Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
- January 6, 2023 - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
- January 4, 2023 - Transgene announces Financial Calendar for 2023
- December 15, 2022 - Transgene Announces Upcoming Investor Meetings
- November 14, 2022 - Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
- November 7, 2022 - Transgene reports business update and Q3 2022 financial position
- November 2, 2022 - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- September 12, 2022 - Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
- September 7, 2022 - Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
- August 31, 2022 - Transgene announces Upcoming Investor Meetings
- June 28, 2022 - Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
- June 27, 2022 - Transgene and BioInvent announce positive progress for BT-001
- June 6, 2022 - Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- May 27, 2022 - Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
- May 25, 2022 - Transgene’s Combined General Meeting of May 25, 2022
- May 17, 2022 - Transgene Announces Upcoming Investor Meetings
- May 10, 2022 - All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
- April 8, 2022 - Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
- April 7, 2022 - Availability of Transgene’s 2021 Universal Registration Document
- April 5, 2022 - Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
- March 31, 2022 - Transgene’s Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman
- March 16, 2022 - Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
- March 9, 2022 - Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
- March 9, 2022 - Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
- February 10, 2022 - Transgene appoints Steven Bloom as Chief Business Officer
- January 20, 2022 - Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
- January 18, 2022 - Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
- January 6, 2022 - Transgene announces Financial Calendar for 2022
- December 15, 2021 - Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
- November 22, 2021 - Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
- November 4, 2021 - Transgene reports business update and Q3 2021 financial position
- October 1, 2021 - Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
- September 22, 2021 - Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
- September 16, 2021 - Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
- September 13, 2021 - Transgene Announces Upcoming Investor Meetings
- September 1, 2021 - Transgene Participates in New Cancer Research Consortium
- June 28, 2021 - First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- June 24, 2021 - First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
- June 22, 2021 - Transgene announces the success of its Capital Increase via a Private Placement
- June 21, 2021 - Transgene Launches a Capital Increase via a Private Placement
- June 8, 2021 - Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
- May 27, 2021 - Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
- May 26, 2021 - Combined General Meeting of May 26, 2021
- April 27, 2021 - Transgene reports business update and end Q1 2021 financial position
- April 12, 2021 - Transgene Announces Upcoming Investor Meetings
- April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
- April 7, 2021 - Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
- April 1, 2021 - Availability of Transgene’s 2020 Universal Registration Document
- March 10, 2021 - Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
- March 10, 2021 - Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
- March 2, 2021 - Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
- March 1, 2021 - Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
- January 21, 2021 - First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- January 19, 2021 - Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
- January 14, 2021 - Transgene Appoints Gaëlle Stadtler as Director of Human Resources
- December 21, 2020 - Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
- December 17, 2020 - Transgene Announces Financial Calendar for 2021
- December 16, 2020 - Transgene Announces Investor Meetings for January 2021
- December 3, 2020 - Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
- December 3, 2020 - Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
- November 9, 2020 - Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- November 9, 2020 - Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
- November 5, 2020 - Transgene reports business update and end Q3 2020 financial position
- November 5, 2020 - Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
- October 27, 2020 - Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- October 19, 2020 - Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- October 15, 2020 - Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- October 6, 2020 - Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
- September 16, 2020 - Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022
- September 9, 2020 - Transgene Announces Upcoming Investor Meetings
- September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
- August 4, 2020 - Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
- July 22, 2020 - Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
- July 9, 2020 - Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
- June 22, 2020 - Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
- June 22, 2020 - Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
- May 27, 2020 - Combined General Meeting of May 27, 2020
- May 15, 2020 - Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
- May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
- May 6, 2020 - Transgene reports Q1 2020 financial position and business update
- May 4, 2020 - Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses
- April 3, 2020 - Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19
- April 3, 2020 - Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
- March 11, 2020 - Major R&D milestones achieved in 2019 and strong clinical activity in 2020
- March 3, 2020 - Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
- February 20, 2020 - First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
- January 7, 2020 - Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
- December 18, 2019 - Transgene Announces Financial Calendar for 2020
- December 12, 2019 - Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
- December 11, 2019 - Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
- December 9, 2019 - Transgene Announces Investor Meetings for January 2020
- November 14, 2019 - Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
- October 22, 2019 - Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
- September 30, 2019 - Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
- September 18, 2019 - Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
- September 16, 2019 - Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
- August 29, 2019 - Transgene Announces Upcoming Investor Meetings
- August 7, 2019 - Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
- August 2, 2019 - Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
- July 18, 2019 - Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
- July 10, 2019 - Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
- July 2, 2019 - Success of Transgene’s €48.7 Million Rights Issue
- June 14, 2019 - Transgene Announces the Launch of a Rights Issue
- June 5, 2019 - Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
- May 27, 2019 - Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
- May 22, 2019 - Combined General Meeting of May 22, 2019
- May 13, 2019 - Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019
- May 13, 2019 - Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
- May 9, 2019 - Transgene Announces Upcoming Investor Meetings
- May 9, 2019 - Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
- May 2, 2019 - Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
- March 26, 2019 - Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
- March 20, 2019 - Transgene: A positive 2018, moving ahead with a strong portfolio
- March 18, 2019 - Transgene secures a €20 Million Revolving Credit Facility with Natixis
- March 13, 2019 - NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
- March 5, 2019 - Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
- December 20, 2018 - Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
- December 17, 2018 - Transgene Announces Financial Calendar for 2019
- December 5, 2018 - Transgene Announces Upcoming Investor Meetings
- November 12, 2018 - Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
- November 7, 2018 - Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
- November 7, 2018 - Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
- October 30, 2018 - NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
- October 25, 2018 - €26.6 million in cash and cash equivalents as of September 30, 2018
- October 17, 2018 - First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
- October 10, 2018 - Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
- October 2, 2018 - Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
- September 24, 2018 - Transgene unveils myvac™, an individualized immunotherapy against solid tumors
- September 19, 2018 - Transgene Presents 2018 Half-Year Results and Business Update
- September 3, 2018 - Transgene Announces Upcoming Investor Meetings
- August 20, 2018 - Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
- July 10, 2018 - Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
- June 4, 2018 - Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
- May 24, 2018 - Transgene Announces Upcoming Investor Meetings
- May 23, 2018 - Combined General Meeting of May 23, 2018
- May 17, 2018 - Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
- May 2, 2018 - Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
- April 26, 2018 - €35.6 Million in Cash and Cash Equivalents as of March 31, 2018
- April 18, 2018 - Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
- March 21, 2018 - Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
- March 15, 2018 - Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
- January 17, 2018 - First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
- January 16, 2018 - First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
- December 21, 2017 - Transgene Announces Financial Calendar for 2018
- December 18, 2017 - Transgene Announces Upcoming Investor Meetings
- December 6, 2017 - BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
- November 10, 2017 - Transgene successfully raises € 14.4 million from U.S. and European investors
- November 9, 2017 - Transgene launches a capital increase by way of an accelerated book build offering
- October 30, 2017 - Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
- October 26, 2017 - First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
- October 23, 2017 - TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
- October 19, 2017 - Third Quarter Marked by Progress in Clinical Development and Research
- October 17, 2017 - Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
- October 12, 2017 - Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
- October 2, 2017 - Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
- September 21, 2017 - Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
- September 19, 2017 - First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
- September 13, 2017 - First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
- September 11, 2017 - Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
- September 7, 2017 - Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
- August 31, 2017 - Transgene Announces Upcoming Investor Meetings
- July 31, 2017 - First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
- July 24, 2017 - Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
- June 29, 2017 - Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
- June 22, 2017 - Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
- June 8, 2017 - Combined General Meeting of June 8, 2017
- April 25, 2017 - €50.7 Million in Cash and Cash Equivalents as of March 31, 2017
- April 25, 2017 - Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
- April 24, 2017 - SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
- April 19, 2017 - Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
- April 12, 2017 - Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
- April 10, 2017 - Transgene Announces Upcoming Investor Meetings and R&D Day
- March 30, 2017 - Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
- March 20, 2017 - Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
- March 13, 2017 - First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
- February 13, 2017 - Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
- January 5, 2017 - Transgene Announces Financial Calendar for 2017
- December 22, 2016 - Transgene Announces Upcoming Investor Events
- December 7, 2016 - UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb
- November 14, 2016 - Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting
- November 10, 2016 - Successful Completion of Transgene’s Rights Issue – Gross proceeds of circa €46.4 million
- October 28, 2016 - Transgene Announces Publication in OncoImmunology of Pre-Clinical Data Demonstrating Delivery of a Fully Functional Immune Checkpoint Inhibitor (ICI) with Anti-Tumor Efficacy by a New Generation of Oncolytic Viral Immunotherapy
- October 20, 2016 - Transgene Reports Third Quarter 2016 Financial Results
- October 20, 2016 - Transgene Announces Rights Issue
- October 17, 2016 - First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
- October 11, 2016 - Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
- October 5, 2016 - Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines
- September 5, 2016 - Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
- September 1, 2016 - Transgene Announces Participation at Upcoming Investor Events
- July 21, 2016 - Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
- May 31, 2016 - Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
- May 25, 2016 - Composition of the Board of Directors and Statutory Auditors
- April 21, 2016 - Transgene Reports First Quarter 2016 Business Update
- April 19, 2016 - Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)
- March 17, 2016 - Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team
- March 8, 2016 - Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)
- March 2, 2016 - Transgene Announces Participation at Upcoming Investor Events
- February 3, 2016 - Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset
- January 28, 2016 - EIB lends EUR 20m to Transgene
- January 8, 2016 - Transgene Announces Financial Calendar for 2016
- January 7, 2016 - Transgene enters new phase in its strategic development
- January 6, 2016 - Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
- December 23, 2015 - Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
- November 12, 2015 - Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
- November 4, 2015 - Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
- October 21, 2015 - Transgene Reports Third Quarter 2015 Financial Results
- September 23, 2015 - Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
- September 10, 2015 - Transgene Reports Financial Results for First Six Months of 2015 (interim report)
- September 8, 2015 - Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
- August 19, 2015 - Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
- June 29, 2015 - Transgene plans restructuring to focus on research and development
- June 1, 2015 - Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
- May 18, 2015 - Transgene Announces Participation at Upcoming Investor Events
- April 23, 2015 - Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
- April 22, 2015 - Transgene Reports First Quarter 2015 Financial Results
- April 21, 2015 - Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
- April 16, 2015 - Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
- March 24, 2015 - Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)
- March 19, 2015 - Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR
- January 8, 2015 - Transgene Announces Financial Calendar for 2015
- October 21, 2014 - Transgene Announces Third Quarter 2014 Financial Results
- September 8, 2014 - Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010
- April 22, 2014 - Transgene Reports First Quarter 2014 Financial Results
- March 26, 2014 - Transgene Reports Fiscal Year 2013 Results and Provides Business Update
Sorted by product
- September 14, 2024 - Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
- July 22, 2024 - Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
- October 10, 2023 - Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
- May 25, 2023 - Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
- June 28, 2022 - Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
- June 27, 2022 - Transgene and BioInvent announce positive progress for BT-001
- March 9, 2022 - Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
- January 20, 2022 - Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
- May 27, 2021 - Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
- March 1, 2021 - Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
- January 19, 2021 - Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
- December 21, 2020 - Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
- November 9, 2020 - Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- October 15, 2020 - Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- June 22, 2020 - Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
- June 22, 2020 - Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
- May 15, 2020 - Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
- March 3, 2020 - Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
- December 11, 2019 - Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
- October 14, 2024 - Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
- June 5, 2023 - Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
- March 15, 2023 - Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- November 2, 2022 - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- June 24, 2021 - First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
- March 10, 2021 - Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
- December 3, 2020 - Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
- November 9, 2020 - Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
- October 27, 2020 - Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- October 19, 2020 - Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- July 22, 2020 - Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
- September 30, 2019 - Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
- June 5, 2019 - Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
- December 20, 2018 - Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
- September 19, 2017 - First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
- October 11, 2016 - Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
- November 7, 2024 - Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- June 3, 2024 - Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 6, 2024 - Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
- March 5, 2024 - Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
- January 8, 2024 - Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
- June 6, 2023 - Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- April 18, 2023 - New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
- April 6, 2023 - Availability of Transgene’s 2022 Universal Registration Document
- April 4, 2023 - Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
- March 15, 2023 - Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- June 6, 2022 - Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- May 27, 2022 - Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
- April 8, 2022 - Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
- March 9, 2022 - Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
- November 22, 2021 - Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
- June 28, 2021 - First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- January 21, 2021 - First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- November 5, 2020 - Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
- October 6, 2020 - Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
- July 9, 2020 - Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
- May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
- January 7, 2020 - Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
- September 16, 2019 - Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
- July 10, 2019 - Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
- May 13, 2019 - Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
- March 5, 2019 - Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
- September 16, 2021 - Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
- April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
- September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
- February 20, 2020 - First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
- July 18, 2019 - Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
- June 5, 2019 - Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
- October 17, 2018 - First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
- August 20, 2018 - Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
- July 10, 2018 - Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
- October 26, 2017 - First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
- August 27, 2024 - Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
- May 10, 2023 - Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
- April 17, 2023 - Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
- March 15, 2023 - Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- January 6, 2023 - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25, 2023 - Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
- May 10, 2023 - Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
- January 6, 2023 - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
- January 4, 2023 - Transgene announces Financial Calendar for 2023
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- September 12, 2022 - Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
- June 28, 2022 - Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
- June 27, 2022 - Transgene and BioInvent announce positive progress for BT-001
- January 18, 2022 - Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
- December 15, 2021 - Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
- September 16, 2021 - Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
- September 1, 2021 - Transgene Participates in New Cancer Research Consortium
- June 8, 2021 - Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
- May 27, 2021 - Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
- March 2, 2021 - Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
- March 1, 2021 - Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
- January 19, 2021 - Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
- December 21, 2020 - Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
- November 9, 2020 - Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
- June 22, 2020 - Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
- June 22, 2020 - Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
- May 15, 2020 - Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
- December 11, 2019 - Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
- May 2, 2019 - Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
- March 26, 2019 - Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
- November 7, 2018 - Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
- November 7, 2018 - Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
- October 2, 2018 - Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
- December 6, 2017 - BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
- October 2, 2017 - Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
- September 21, 2017 - Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
- November 7, 2024 - Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
- November 5, 2024 - Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 6, 2024 - Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
- March 5, 2024 - Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
- January 8, 2024 - Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
- June 6, 2023 - Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- April 18, 2023 - New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
- June 6, 2022 - Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- May 27, 2022 - Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
- April 8, 2022 - Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
- March 9, 2022 - Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
- June 28, 2021 - First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- March 2, 2021 - Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
- January 21, 2021 - First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- October 6, 2020 - Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
- July 9, 2020 - Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
- June 22, 2020 - Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
- May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
- September 16, 2019 - Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
- July 10, 2019 - Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
- May 13, 2019 - Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
- March 5, 2019 - Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
- November 7, 2018 - Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
- October 30, 2018 - NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
- October 2, 2018 - Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
- September 24, 2018 - Transgene unveils myvac™, an individualized immunotherapy against solid tumors
- November 7, 2024 - Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
- November 7, 2024 - Transgene Reports Business, Pipeline and Financial Update for Q3 2024
- November 5, 2024 - Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
- October 14, 2024 - Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- September 24, 2024 - Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
- September 14, 2024 - Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
- September 10, 2024 - Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
- September 9, 2024 - Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
- September 5, 2024 - Transgene to Participate in HTID Conference and Investor Access Forum in Paris
- August 27, 2024 - Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
- July 30, 2024 - Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH
- July 22, 2024 - Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
- June 3, 2024 - Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- May 15, 2024 - Transgene’s Combined General Meeting of May 15, 2024
- May 14, 2024 - Transgene provides business and financial update for Q1 2024
- April 24, 2024 - Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024
- April 11, 2024 - Availability of Transgene’s 2023 Universal Registration Document
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 27, 2024 - Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- March 27, 2024 - Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
- March 18, 2024 - Transgene Announces Upcoming Investor Meetings
- March 6, 2024 - Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
- March 5, 2024 - Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
- January 22, 2024 - Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
- January 22, 2024 - Transgene Announces Financial Calendar for 2024
- January 8, 2024 - Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
- December 21, 2023 - Transgene Announces Upcoming Investor Meetings
- December 5, 2023 - Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
- November 7, 2023 - Transgene reports business update and Q3 2023 financial position
- October 10, 2023 - Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
- September 20, 2023 - Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
- September 14, 2023 - Transgene Announces Upcoming Investor Meetings
- July 17, 2023 - Transgene receives $15.3 Million from the Sale of Securities Held for Sale
- June 6, 2023 - Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- June 5, 2023 - Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25, 2023 - Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
- May 10, 2023 - Transgene provides business update and Q1 2023 financial position
- May 10, 2023 - Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
- May 5, 2023 - Transgene’s Combined General Meeting of May 5, 2023
- May 5, 2023 - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- April 18, 2023 - New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
- April 17, 2023 - Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
- April 12, 2023 - Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
- April 11, 2023 - Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
- April 6, 2023 - Availability of Transgene’s 2022 Universal Registration Document
- April 4, 2023 - Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
- March 27, 2023 - Transgene Announces Upcoming Investor Meetings
- March 16, 2023 - Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
- March 15, 2023 - Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- March 9, 2023 - Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
- January 6, 2023 - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
- January 4, 2023 - Transgene announces Financial Calendar for 2023
- December 15, 2022 - Transgene Announces Upcoming Investor Meetings
- November 14, 2022 - Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
- November 7, 2022 - Transgene reports business update and Q3 2022 financial position
- November 2, 2022 - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
- September 12, 2022 - Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
- September 7, 2022 - Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
- August 31, 2022 - Transgene announces Upcoming Investor Meetings
- June 28, 2022 - Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
- June 27, 2022 - Transgene and BioInvent announce positive progress for BT-001
- June 6, 2022 - Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- May 27, 2022 - Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
- May 25, 2022 - Transgene’s Combined General Meeting of May 25, 2022
- May 17, 2022 - Transgene Announces Upcoming Investor Meetings
- May 10, 2022 - All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
- April 8, 2022 - Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
- April 7, 2022 - Availability of Transgene’s 2021 Universal Registration Document
- April 5, 2022 - Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
- March 31, 2022 - Transgene’s Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman
- March 16, 2022 - Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
- March 9, 2022 - Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
- March 9, 2022 - Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
- February 10, 2022 - Transgene appoints Steven Bloom as Chief Business Officer
- January 20, 2022 - Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
- January 18, 2022 - Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
- January 6, 2022 - Transgene announces Financial Calendar for 2022
- December 15, 2021 - Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
- November 22, 2021 - Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
- November 4, 2021 - Transgene reports business update and Q3 2021 financial position
- October 1, 2021 - Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
- September 22, 2021 - Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
- September 16, 2021 - Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
- September 13, 2021 - Transgene Announces Upcoming Investor Meetings
- September 1, 2021 - Transgene Participates in New Cancer Research Consortium
- June 28, 2021 - First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- June 24, 2021 - First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
- June 22, 2021 - Transgene announces the success of its Capital Increase via a Private Placement
- June 21, 2021 - Transgene Launches a Capital Increase via a Private Placement
- June 8, 2021 - Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
- May 27, 2021 - Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
- May 26, 2021 - Combined General Meeting of May 26, 2021
- April 27, 2021 - Transgene reports business update and end Q1 2021 financial position
- April 12, 2021 - Transgene Announces Upcoming Investor Meetings
- April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
- April 7, 2021 - Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
- April 1, 2021 - Availability of Transgene’s 2020 Universal Registration Document
- March 10, 2021 - Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
- March 10, 2021 - Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
- March 2, 2021 - Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
- March 1, 2021 - Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
- January 21, 2021 - First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- January 19, 2021 - Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
- January 14, 2021 - Transgene Appoints Gaëlle Stadtler as Director of Human Resources
- December 21, 2020 - Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
- December 17, 2020 - Transgene Announces Financial Calendar for 2021
- December 16, 2020 - Transgene Announces Investor Meetings for January 2021
- December 3, 2020 - Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
- December 3, 2020 - Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
- November 9, 2020 - Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- November 9, 2020 - Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
- November 5, 2020 - Transgene reports business update and end Q3 2020 financial position
- November 5, 2020 - Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
- October 27, 2020 - Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- October 19, 2020 - Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
- October 15, 2020 - Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
- October 6, 2020 - Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
- September 16, 2020 - Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022
- September 9, 2020 - Transgene Announces Upcoming Investor Meetings
- September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
- August 4, 2020 - Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
- July 22, 2020 - Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
- July 9, 2020 - Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
- June 22, 2020 - Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
- June 22, 2020 - Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
- May 27, 2020 - Combined General Meeting of May 27, 2020
- May 15, 2020 - Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
- May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
- May 6, 2020 - Transgene reports Q1 2020 financial position and business update
- May 4, 2020 - Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses
- April 3, 2020 - Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19
- April 3, 2020 - Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
- March 11, 2020 - Major R&D milestones achieved in 2019 and strong clinical activity in 2020
- March 3, 2020 - Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
- February 20, 2020 - First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
- January 7, 2020 - Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
- December 18, 2019 - Transgene Announces Financial Calendar for 2020
- December 12, 2019 - Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
- December 11, 2019 - Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
- December 9, 2019 - Transgene Announces Investor Meetings for January 2020
- November 14, 2019 - Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
- October 22, 2019 - Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
- September 30, 2019 - Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
- September 18, 2019 - Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
- September 16, 2019 - Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
- August 29, 2019 - Transgene Announces Upcoming Investor Meetings
- August 7, 2019 - Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
- August 2, 2019 - Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
- July 18, 2019 - Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
- July 10, 2019 - Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
- July 2, 2019 - Success of Transgene’s €48.7 Million Rights Issue
- June 14, 2019 - Transgene Announces the Launch of a Rights Issue
- June 5, 2019 - Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
- May 27, 2019 - Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
- May 22, 2019 - Combined General Meeting of May 22, 2019
- May 13, 2019 - Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019
- May 13, 2019 - Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
- May 9, 2019 - Transgene Announces Upcoming Investor Meetings
- May 9, 2019 - Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
- May 2, 2019 - Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
- March 26, 2019 - Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
- March 20, 2019 - Transgene: A positive 2018, moving ahead with a strong portfolio
- March 18, 2019 - Transgene secures a €20 Million Revolving Credit Facility with Natixis
- March 13, 2019 - NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
- March 5, 2019 - Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
- December 20, 2018 - Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
- December 17, 2018 - Transgene Announces Financial Calendar for 2019
- December 5, 2018 - Transgene Announces Upcoming Investor Meetings
- November 12, 2018 - Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
- November 7, 2018 - Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
- November 7, 2018 - Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
- October 30, 2018 - NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
- October 25, 2018 - €26.6 million in cash and cash equivalents as of September 30, 2018
- October 17, 2018 - First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
- October 10, 2018 - Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
- October 2, 2018 - Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
- September 24, 2018 - Transgene unveils myvac™, an individualized immunotherapy against solid tumors
- September 19, 2018 - Transgene Presents 2018 Half-Year Results and Business Update
- September 3, 2018 - Transgene Announces Upcoming Investor Meetings
- August 20, 2018 - Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
- July 10, 2018 - Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
- June 4, 2018 - Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
- May 24, 2018 - Transgene Announces Upcoming Investor Meetings
- May 23, 2018 - Combined General Meeting of May 23, 2018
- May 17, 2018 - Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
- May 2, 2018 - Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
- April 26, 2018 - €35.6 Million in Cash and Cash Equivalents as of March 31, 2018
- April 18, 2018 - Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
- March 21, 2018 - Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
- March 15, 2018 - Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
- January 17, 2018 - First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
- January 16, 2018 - First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
- December 21, 2017 - Transgene Announces Financial Calendar for 2018
- December 18, 2017 - Transgene Announces Upcoming Investor Meetings
- December 6, 2017 - BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
- November 10, 2017 - Transgene successfully raises € 14.4 million from U.S. and European investors
- November 9, 2017 - Transgene launches a capital increase by way of an accelerated book build offering
- October 30, 2017 - Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
- October 26, 2017 - First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
- October 23, 2017 - TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
- October 19, 2017 - Third Quarter Marked by Progress in Clinical Development and Research
- October 17, 2017 - Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
- October 12, 2017 - Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
- October 2, 2017 - Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
- September 21, 2017 - Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
- September 19, 2017 - First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
- September 13, 2017 - First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
- September 11, 2017 - Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
- September 7, 2017 - Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
- August 31, 2017 - Transgene Announces Upcoming Investor Meetings
- July 31, 2017 - First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
- July 24, 2017 - Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
- June 29, 2017 - Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
- June 22, 2017 - Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
- June 8, 2017 - Combined General Meeting of June 8, 2017
- April 25, 2017 - €50.7 Million in Cash and Cash Equivalents as of March 31, 2017
- April 25, 2017 - Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
- April 24, 2017 - SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
- April 19, 2017 - Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
- April 12, 2017 - Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
- April 10, 2017 - Transgene Announces Upcoming Investor Meetings and R&D Day
- March 30, 2017 - Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
- March 20, 2017 - Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
- March 13, 2017 - First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
- February 13, 2017 - Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
- January 5, 2017 - Transgene Announces Financial Calendar for 2017
- December 22, 2016 - Transgene Announces Upcoming Investor Events
- December 7, 2016 - UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb
- November 14, 2016 - Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting
- November 10, 2016 - Successful Completion of Transgene’s Rights Issue – Gross proceeds of circa €46.4 million
- October 28, 2016 - Transgene Announces Publication in OncoImmunology of Pre-Clinical Data Demonstrating Delivery of a Fully Functional Immune Checkpoint Inhibitor (ICI) with Anti-Tumor Efficacy by a New Generation of Oncolytic Viral Immunotherapy
- October 20, 2016 - Transgene Reports Third Quarter 2016 Financial Results
- October 20, 2016 - Transgene Announces Rights Issue
- October 17, 2016 - First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
- October 11, 2016 - Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
- October 5, 2016 - Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines
- September 5, 2016 - Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
- September 1, 2016 - Transgene Announces Participation at Upcoming Investor Events
- July 21, 2016 - Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
- May 31, 2016 - Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
- May 25, 2016 - Composition of the Board of Directors and Statutory Auditors
- April 21, 2016 - Transgene Reports First Quarter 2016 Business Update
- April 19, 2016 - Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)
- March 17, 2016 - Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team
- March 8, 2016 - Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)
- March 2, 2016 - Transgene Announces Participation at Upcoming Investor Events
- February 3, 2016 - Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset
- January 28, 2016 - EIB lends EUR 20m to Transgene
- January 8, 2016 - Transgene Announces Financial Calendar for 2016
- January 7, 2016 - Transgene enters new phase in its strategic development
- January 6, 2016 - Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
- December 23, 2015 - Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
- November 12, 2015 - Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
- November 4, 2015 - Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
- October 21, 2015 - Transgene Reports Third Quarter 2015 Financial Results
- September 23, 2015 - Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
- September 10, 2015 - Transgene Reports Financial Results for First Six Months of 2015 (interim report)
- September 8, 2015 - Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
- August 19, 2015 - Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
- June 29, 2015 - Transgene plans restructuring to focus on research and development
- June 1, 2015 - Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
- May 18, 2015 - Transgene Announces Participation at Upcoming Investor Events
- April 23, 2015 - Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
- April 22, 2015 - Transgene Reports First Quarter 2015 Financial Results
- April 21, 2015 - Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
- April 16, 2015 - Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
- March 24, 2015 - Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)
- March 19, 2015 - Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR
- January 8, 2015 - Transgene Announces Financial Calendar for 2015
- October 21, 2014 - Transgene Announces Third Quarter 2014 Financial Results
- September 8, 2014 - Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010
- April 22, 2014 - Transgene Reports First Quarter 2014 Financial Results
- March 26, 2014 - Transgene Reports Fiscal Year 2013 Results and Provides Business Update
